ARTICLE | Clinical News
VB-201: Phase II data
February 23, 2015 8:00 AM UTC
VBL discontinued development of VB-201 to treat UC after top-line data from a double-blind, European Phase II trial in 112 patients showed that daily oral 160 mg VB-201 for 24 weeks missed the primary...